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Abstract: Events of the past decade or so argue that there is 
little support in the literature for much of the specialty's treat-
ment portfolio. The resulting call for 'evidence-based' treatment 
(not to mention the obvious intellectual bankruptcy of much of 
the clinical literature) has prompted many to argue that the 
randomized clinical trial (ACT) represents the future of or-
thodontic clinical investigation. The ACT, after all, is medicine's 
gold standard; what more is there to say? A popular, but 
ultimately divisive, corollary of this mimicry is the smug ten-
dency to discount all other sources of data. In the face of a 
need for information, this attitude is also a wasteful conceit: in 
the end, the ACT can be applied only to a very narrow spec-
trum of orthodontic questions. Randomization implies equal 
susceptibility. Any prospective participant would have to be 
informed of this equality as part of the informed consent pro-
cess. Unfortunately, it would be nearly impossible to enroll 
fully-informed subjects into any study whose alternatives are of 
markedly different morbidity: extraction versus non-extraction 
or orthodontics versus surgery. Thus, when measured against 
the most vexing clinical questions, the orthodontic ACT is al-
most by definition an amusing diversion - expensive, but rela-
tively trivial in scope. Uke it or not, it seems reasonable to 
conclude that most of the specialty's comparative clinical data 
will have to be generated by way of non-randomized designs 
In which care Is taken to minimize the various known sources 
of bias. There probably is no other way. 
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In the acti1:ities of clinical therapy ... the formulation 
of hypotheses and counter-hypotheses is a trivial creative 
challenge. It takes absolutely no insight to ask the obvious 
question, 'I wander whether bypass surgery is good for 
people t.l.'ith coronary artery disease!' It also takes no in· 
sight to establish a counter-hypothesis .... The tmly cre-
ative problems of clinical management are in 
methodology, not in hypothesis formulation. Where the 
devil can tve get appropriate group.~ of people and data 
to compare the therapies in an unbiased, objecti1.•e way so 
that the questions u·ill get effective, useful anstvers? (1) 
The present communication is an after-the-fact addition 
to Prospective Clinical Research in Orthodontics, a meet· 
ing designed to showcase yet another round of progress 
reports from 'the first controlled studies' in orthodontics. 
Given that the quasi-experimental Saint Louis University/ 
University of Michigan Class II treatment comparisons 
are productive, albeit philosophically discrepant charter 
members of this pioneering cohort, their lowly estate is 
significant and worthy of extended comment. 
Like children playing at being adults, many in or-
thodontics feel that the road to scientific maturity lies in 
imitating medicine, no matter what the cost and regardless 
of outcome. There is a tendency, therefore, to see the 
means of investigation as an end in itself and, by exten· 
sion, to discount all other sources of data. For example, it 
is a common strategy to show slides depicting some sort 
of scala naturae in which clinical research designs ascend 
from the slime of retrospection to the perfection of the 
randomized clinical trial (RCT). At a time when the 
specialty is under attack from a variety of barbarian 
hordes and its main defenses are timely, adequately de-
signed clinical studies, the . blanket assertion that truly 
meaningful data can come only from an RCT is self-serv-
ing and inappropriate; it is the equivalent of saying, 'let 
them eat cake'. A few dyspeptic comments are in order. 
History teaches that orthodontists tend to be profes-
sionally successful, regardless of their educational back· 
ground or choice of appliances; few look to 'science' as a 
source of practical clinical guidance. Perhaps as a result, 
disagreement was, until recently, largely recreational and 
for the most part limited to superficial tactical details, 
such as type of appliance (edgewise, bioprogressive, 
headgear, bionator, etc.), slot size and angulation, inter-
bracket distance, and the like. It was harmless sport 
because, at the same time, there was general agreement 
concerning the basic strategies of treatment. Extraction, 
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for example, was seen as an answer to crowding and 
protrusion; surgery, as an answer to severe skeletal discre-
pancies. Times have changed. For a variety of reasons -
specialist/generalist turf wars, fear of litigation, busyness 
problems - entire treatment strategies have come under 
attack, both from within and without the specialty. These 
attacks have taken their toll. 
Some of our critics, for example, argue that bicuspids 
should never be extracted or that surgery is tantamount to 
malpractice. The bitterness of the disagreement and the 
fervor of the participants is a threat to the public health; 
it threatens the well being of the specialty; it distorts 
clinical judgement. A major problem with the various 
revisionist arguments is that they call for alternatives that 
have never. be.en shown to be as orthodontically effective as 
the treatments they would replace. For example, one 
would have to achieve 12 mm of stable expansion to equal 
the 5 mm of space per quadrant created routinely by 
bicuspid extraction (the width of .a bicuspid minus the 
ancho~age lost during space closure). Wishful thinking 
aside, the literature argues that contemporary 'arch-devel-
J • 
opment' methods fall far short of this requirement, as do 
fanciful functional-appliance substitutes for surgery ('bite 
forward ... forever'). Accordingly, it is important that we 
examine carefully the arguments against extraction and 
surgery, because, if they are true, it would mean that we 
have no safe, effective treatment for a large segment of the 
orthodontic population. Unfortunately, in contrast to 
superficial technical details, many of our basic orthodon-
tic strategies are surprisingly difficult to study in real time. 
Given a desire to compare, say, arch leveling with 
0.018-inch and 0.022-inch slots or early treatment with 
headgear and bionator, a careful 'retrospective' compari-
son probably will provide data that are 'good enough', 
both because it is easy to obtain samples that were similar 
before treatment and because the contrasts themselves are 
only of mild-to-moderate importance. In contrast, if one 
wants to document .the supposed superiority of say, non-
extraction edgewise orthodontic treatment {better func-
tion, more pleasing profiles, greater stability, etc.), one 
cannot simply round up a few ex-patients and compare 
outcomes. Comparisons between groups formed on the 
basis of a clinician's treatment assignment tend to be 
compromised by 'susceptibility bias', a systematic segrega-
tion driven by the simple fact that many types of maloc-
clusion seem uniquely susceptible to a specific treatment. 
For example, if extraction and non-extraction patients 
were systematically different before treatment (crowded 
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and protrusive versus spaced and 'flat'), differences after 
treatment would defy interpretation. To effect a meaning· 
ful comparison, therefore, outcomes must be compared in 
patients who initially were similar and thus equally sus-
ceptible to both treatments. 
Clearly, a well-designed randomized clinical trial would 
serve to eliminate susceptibility bias, along with a variety 
of other biases, both known and unknown. A key prereq· 
uisite to the conduct of a clinical trial is that there be true 
uncertainty about the relative efficacy of the various arms 
of the trial ('equipoise'; (2)). Individual orthodontists, 
however, commonly do not share the uncertainty of the 
refereed literature. As a result, they might not agree with, 
and thus would be unable to render, a treatment dictated 
by random assignment. Baumrind's method of 'clinician· 
preferred' treatment assignment (3) seems to address these 
requirements and problems by providing an empirical 
definition of uncertainty and by ensuring that treatment is 
prosecuted by a clinician who happens to agree with the 
randomization. It is my opinion, however, that this inge-
nious approach does not solve the problem of informed 
consent. 
Because great pains must be taken to determine and 
document equal susceptibility to all treatments, a partici· 
pant in a randomized clinical trial is usually subjected to 
a more thorough analysis than is the average orthodontic 
patient. From the standpoint of hypothesis testing, there· 
fore, it is probable that the RCT would serve to eliminate 
bias and to equalize experimental conditions. From the 
standpoint of a prospective subject, however, randomiza· 
tion can never equalize the anticipated pain, discomfort, 
and inconvenience of the various arms of the trial. Unfor· 
tunately, many of the most pressing questions in or· 
thodontics - those asked in the clinic and. in court, rather 
than those offered up for ritual slaughter at meetings and 
in monographs - involve treatments that differ greatly in 
terms of anticipated pain, discomfort, and inconvenience. 
Thus, if all things (except the treatments to be compared) 
really are equal and the patient knows that they are equal, 
how can a sample ever be recruited? 
What sort of subjects, for example, would agree to 
surgery if they understood - i.e. were fully-informed -
that they could be treated equally well orthodontically? 
('Mrs. Jones, your daughter can be treated orthodontically 
or surgically; however, we flipped a coin and it came up 
surgery. Sign here.') Some no doubt would agree to partie· 
ipate, perhaps in the hope that they will be randomized to 
the less morbid arm of the trial. If they are lucky, fine; if 
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not, they can always withdraw. Unfortunately, even if a 
few surgery patients or a few extraction patients happen 
to make it this far, there is one last hurdle: would 
fully-informed subjects permit themselves to be random-
ized to a surgery or extraction arm if pains were taken to 
elicit a preference? As noted by Kodish et al. (4), 'the 
autonomy principle dictates that patients' personal values 
and motivations ~e given the highest priority in reaching 
a treatment decision.' I would argue, therefore, that many 
(but surely not all) non-trivial orthodontic trials can suc-
ceed only to the extent that a prospective subject's right 
to informed consent is abridged. Many disagree with this 
judgement, especially those who seek to bring the enlight-
enment of randomized trials to those toiling in the dark-
ness of retrospective investigation. 
Elsewhere in this issue, Baumrind has noted that he is 
'not greatly concerned' by my ethical reservations. As I 
understand it, he feels that empirical uncertainty (i.e. 
among-clinician disagreement) is not the same thing as 
equal susceptibility. Even in the face of uncertainty (as 
defined by evenly divided opinion), one treatment will 
probably turn out to be better than the other. Based on 
this fine distinction between uncertainty and equal effect, 
it is argued that it would be misleading/unnecessary to tell 
prospective subjects that they probably would be served 
equally well by either arm of the trial. I doubt that this 
argument can be sustained. 
In tennis, if you cannot see the ball out, you have to 
call it in. In the clinic, however, if opinion is so evenly 
divided that one treatment option is about as popular as 
the other, I would argue that the two must be assumed, at 
least provisionally, to be equally effective. If it is assumed 
that the two treatments are equal, then this information 
must be shared with prospective subjects. Indeed, in 
Baumrind's approach, among-clinician disagreement is the 
main eligibility requirement. If eligible subjects also must 
be equally susceptible, then from the standpoint both of 
the study and its participants, disagreement also defines 
equal susceptibility. QED. More to the point, if prospec-
tive subjects were informed of the among-clinician dis-
agreement that defined their eligibility and were pressed 
for a preference, how many would allow themselves to be 
assigned the more morbid option? 
It should come as no great surprise, therefore,. that the 
only trials that have managed to honor the details of their 
original application are those designed to compare techni-
cal details, not basic strategies. Although a mean-spirited 
observer might question the need for 10 years of support 
for each of three studies of 'headgear versus function· 
als', others apparently feel that the mere existence of 
these trials signals a scientific coming-of-age for or· 
thodontic clinical research. Unfortunately, in its or· 
thodontic incarnations, the RCT is a somewhat debased 
gold standard. 
In the Wi~ard of 0~. Professor Marvel asked the four 
awed supplicants to 'pay no attention to that man be· 
hind the curtain'. In the world of the orthodontic ran· 
domized clinical trial (surely the metaphorical equivalent 
of the Emerald City), we are asked by other professors 
to be equally awed and equally selective in our atten· 
tion. For example, we are asked (or at least expected) to 
ignore the lack of blinding during and after treatment, 
not to mention the probable impact of the so-called 
'Hawthorne effect'. The. goodness of a treatment out· 
come depends on the orthodontist's efforts and the pa· 
tient's cooperation, both of which might well be 
elevated to supra-normal levels by dint of both parties' 
known participation in a clinical trial. Moreover, be· 
cause of the time and money invested in each of a 
relatively small coterie of subjects, orthodontic RCTs 
sometimes feature vigorous, but scientifically question· 
able, steps to achieve exalted levels of patient compli· 
ance (e.g. periodic telephone calls to restore flagging 
enthusiasm and cooperation). Indeed, even the act of 
taking the occasional peek at the preliminary data ('the 
headgear patients are doing fine, but the functionals are 
lagging behind ... '), presumably for the purpose of issu-
ing breathless communiques and news flashes at various 
meetings throughout the world, is seen by some as a 
violation of the RCT ground rules. Moreover, as al· 
luded to elsewhere in this volume, there are a number 
of practical problems that may prove equally damaging 
to the successful completion of a non-trivial orthodontic 
RCT. 
Orthodontic treatments take years to finish and even 
longer to evaluate. Thus, a truly useful RCT would 
have a time frame (15-20 years) approaching that of a 
major medical trial (and exceeding the residual profes-
sional life of most of the current principal investiga· 
tors). Indeed, an orthodontic trial also would probably 
outlive its working hypothesis. Most damaging, how· 
ever, is the certainty of sample attrition and the atten· 
dant loss of statistical power. If you start with 300, a 
one-in-ten response is adequate; if you start with 30, 
you end up with an exceptionally expensive case report. 
Ultimately, orthodontic investigators will have to assess 
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their goals and priorities. The quest for man-powered 
flight was ennobling, expensive, and the subject of sev· 
eral fascinating Public Broadcasting specials; however, it 
did little for the person faced with, say, the rigors of a 
coach/class flight from Detroit to Dallas. Is it to be 
form or substance? As noted by Feinstein (5): 
A ... misconception is to git:e randomi~ation credit for · 
certain scientific standards and precautions for u·hich it is 
really not responsible .... The misconception just cited -
which confuses the tactic of randomi~ed assignment and 
the strategy of a scientific plan - is particularly impor-
tant, becallse many of the desirable scientific features as· 
sociated with randomi~ed clinical trials ... are really 
attributable to advance scientific planning, not to random-
itation. These desirable features can therefore be obtained 
with suitable planning et.•en when randomi~ation is not 
used. 
In the end, if 'many ·of the desirable scientific features 
associated Jwith randomized clintcal trials' can be 
achieved without randomization, then there is no need 
to limit one's perspectives to narrow, trivial problems 
merely because they lend themselves easily to the Rcr 
genre. The tail need not wag the dog. 
Based on the reasoning outlined in this brief commu· 
nication, the Saint Louis University/University of Mich· 
igan response to the NIDR request for applications 
opted for the substance and promise of a partially retro-
spective design over the form and pretence of a ran· 
domized clinical trial. Our implementation of Feinstein's 
call for 'suitable planning' took the form of a statistical 
algorithm designed to identify samples of patients who, 
at the start of treatment, were similar with ·'respect to 
the features that normally dictate the choice of treat• 
ment strategies (crowding, protrusion, overjet, and the 
like). Given this approach, we were able to go well 
beyond the narrow scope of a prospective trial to exam· 
ine treatment alternatives that could never be random· 
ized to fully-informed subjects (e.g. extraction versus 
non-extraction; orthodontics versus surgery). The results 
of these studies will be examined elsewhere in this is-
sue. In the meantime, I would argue that, for orthodon· 
tics, 'the first controlled studies' are much like teaching 
a dog to play the piano - an interesting achievement, 
but hardly a benchmark against which all other musical 
activities must be judged. 
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Abstrakt 
Faile in den Iemen zehn Jahren lassen erkennen, JaB es in der 
Literatur nur wenig Unterstiitzung fur einen GroBteil des Behand-
lungsportfolios in der Kieferorthopiidie gibt. Die daraus re· 
suhierende Nachfrage nach 'auf Beweisen basierender' Behandlung 
(abgesehen vom offensichtlichen intellektuellen Bankrott eines 
Grof~teils der klinischen Literatur) hat dazu gefi.ihrt, daB viele be· 
haupten, die klinische Zufallsstudie (Randomized Clinical Trial: 
RCT) sei die Zukunft der klinischen Versuche in Jer Kieferortho· 
piidie. Die RCT ist schlieBiich auch Jer goldene Standard in der 
Medizin; was gibt es da noch zu sagen? Eine beliebte, letztendlich 
aber umstrittene Folge Jieser Nachahmung ist die selbstgefallige 
Neigung dazu, aile anderen Datenquellen zu unterschiit:en. 
Angesichts des Bedarfs an lnformationen ist diese Einstellung 
auBerdem eine verschwenderische Einbildung: let:tendlich kann die 
RCT nur bei einem sehr engen Spektrum von kieferorthopiidischen 
Fragen angewendet werden. Eine zufiillige Zuweisung setzt die Gleich· 
heit der Yorausset:ungen voraus. Jeder potentielle Teilnehmer 
miiBte als Teil des Prinzips der informierten Zustimmung iiber 
diese Gleichheit unterrichtet werden. Leider wiirde es nahezu un• 
moglich sein, voll informierte Personen in irgendeine Studie 
aufzunehmen, deren Behandlungsalternativen groBe Unterschiede in 
den SchadensgraJen beinhalten: Extraktion im Vergleich zur Nich· 
textraktion oder Kieferorthopiidie im Vergleich zur Kieferchirurgie. 
Yerglichen mit den kompliziertesten klinischen Fragen ist somit die 
kieferorthopiidische RCT schon von Jer Definition her eine amii· 
sante Ablenkung·teuer, nber vom Umfnng her relativ belanglos. Ob 
es uns gefallt oder nicht, es scheint eine verniinftige 
SchluBfolgerung zu sein, JaB ein GroBteil der klinischen Yergleichs-
daten in Jer Kieferorthopadie Jurch Designs der nicht-zufalligen 
Zuweisung gewonnen werden muB, wobei darauf geachtet werden 
muB, JaB die verschiedenen bekannten Neigungen minimiert wer· 
den. Wahrscheinlich gibt es keine andere Moglichkeit. 
Resumen 
Eventos en esta ultima Jecada demuestran que hay poco apoyo en 
Ia literatura con respecto a todo lo que incluye Ia carpeta de 
tratamientos de Ia especialidad. La reclamacion del tratamiento 
basado en Ia evidenda (por mencionar Ia falta de material intelec· 
tual dn Ia literatura cllnica) ha impulsado a muchos a argumentar 
que Ia investigation clinica aleatorizada (ICA) represents el futuro 
de Ia investigation cllnica en Ia ortodontica. La ICA es, despues de 
todo Ia norma.en investigaciones medicas. Una tendencia popular, 
pero dh·isiva. es Ia consequencia de estra mimica a descontar todas 
las otras fuentes de datos. Ante Ia necesidad urgente de informa· 
cion, esta actitud es una vanidad malgastadora: a un extrema, Ia 
ICA solo se puede aplicar a un espectro muy limitado en las pre· 
guntas hechas en investigaciones de ortodoncia. Aleatori:ado (al 
a:ar) implica igualdaJ de suseptibilidad. Cualquier participantc: 
prospecto tiene que ser informado de esta igualdad como pane del 
proceso de consentimiento informado. Desafortunadamente, es casi 
imposible obtener participantes totalmente informados en cualquier 
investigacion que conlleve alternativas notablemente diferentes: ex-
traccion contra no-extraer o cirugia contra ortodoncia. Asi que, 
cuando se compara con las preguntas clinicas mis exigentes, el uso 
de ortodoncia de Ia ICA es casi por definicion una proposici6n 
costosa, pero relath·emente trivial en alcan:e. Nos guste o n6, 
parece razonable concluir que Ia mayoria le dos datos cllnicos 
comparatives de Ia especialidaJ tendran que ser generados por medio 
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de disenos no-aleatorizados en el cual se tome precauci6n para mini· 
mi:ar las varias fuentes desconocidas de prejuicios. Probablemente, no 
hay ninguna otra manera. 
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